Subscribe
shutterstock_2162525475_jonathan-weiss
shutterstock_2162525475_jonathan-weiss
19 October 2023Big PharmaLiz Hockley

EU court confirms €60m fine for Teva

Luxemboug court agrees with European Commission that ‘beneficial arrangement’ between Teva and Cephalon delayed generic market entry of sleep disorder drug | Teva and subsidiary Cephalon to pay around €30m each plus costs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva and Eli Lilly end patent clash over migraine drug
28 November 2023   Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva.
article
Teva loses plea against GSK’s $235m ‘skinny label’ win
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Teva and Eli Lilly end patent clash over migraine drug
28 November 2023   Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva.
article
Teva loses plea against GSK’s $235m ‘skinny label’ win
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More on this story

Big Pharma
Teva and Eli Lilly end patent clash over migraine drug
28 November 2023   Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva.
article
Teva loses plea against GSK’s $235m ‘skinny label’ win
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims